Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Antiplatelet Therapy and Coronary Interventions: Childhood Friends or Permanent Partners?

Antiplatelet Therapy and Coronary Interventions: Childhood Friends or Permanent Partners? Coronary intervention and antiplatelet therapy have grown side-by-side. Antiplatelet therapy in the form of aspirin was used during the fxst procedures performed by Gruntzig.’ It is interesting to note that Gruntzig’s first publication appeared only 6 years after the mechanism of aspirin’s antiplatelet action was elucidated by Roth and Majerus.* Nearly a decade later, the field witnessed the first demonstrations that aspirin led to significant reductions in the rate of periprocedural myocardial infar~tion.~ Seven more years passed before the EPIC investigators showed that a platelet antagonist designed to block glycoprotein IIbLIIa produced clinically meaningful reductions in periprocedural ischemic event^.^ This trial and the subsequent EPILOG study’ also highlighted the need to integrate aggressive antiplatelet therapy into the antithrombotic and parasurgical milieu of interventional cardiology in order to limit hemorrhage and its sequelae. Subsequent advances in platelet physiology and antiplatelet pharmacology have accompanied and in some cases enabled parallel growth in the interventional field. Intracoronary stents clearly represent the most important mechanical advance in interventional cardiology in the past 2 decades. However, the rapidity with which stent technology has been adopted is due largely to the observation by Colombo et al. that dual antiplatelet therapy with aspirin and ticlopidine http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Interventional Cardiology Wiley

Antiplatelet Therapy and Coronary Interventions: Childhood Friends or Permanent Partners?

KLEIMAN, NEAL S.
Journal of Interventional Cardiology , Volume 15 (2) – Apr 1, 2002
Download PDF
3 pages

Loading next page...
 
/lp/wiley/antiplatelet-therapy-and-coronary-interventions-childhood-friends-or-lwB00YxuRb

References (9)

Publisher
Wiley
Copyright
Copyright © 2002 Wiley Subscription Services, Inc., A Wiley Company
ISSN
0896-4327
eISSN
1540-8183
DOI
10.1111/j.1540-8183.2002.tb01042.x
Publisher site
See Article on Publisher Site

Abstract

Coronary intervention and antiplatelet therapy have grown side-by-side. Antiplatelet therapy in the form of aspirin was used during the fxst procedures performed by Gruntzig.’ It is interesting to note that Gruntzig’s first publication appeared only 6 years after the mechanism of aspirin’s antiplatelet action was elucidated by Roth and Majerus.* Nearly a decade later, the field witnessed the first demonstrations that aspirin led to significant reductions in the rate of periprocedural myocardial infar~tion.~ Seven more years passed before the EPIC investigators showed that a platelet antagonist designed to block glycoprotein IIbLIIa produced clinically meaningful reductions in periprocedural ischemic event^.^ This trial and the subsequent EPILOG study’ also highlighted the need to integrate aggressive antiplatelet therapy into the antithrombotic and parasurgical milieu of interventional cardiology in order to limit hemorrhage and its sequelae. Subsequent advances in platelet physiology and antiplatelet pharmacology have accompanied and in some cases enabled parallel growth in the interventional field. Intracoronary stents clearly represent the most important mechanical advance in interventional cardiology in the past 2 decades. However, the rapidity with which stent technology has been adopted is due largely to the observation by Colombo et al. that dual antiplatelet therapy with aspirin and ticlopidine

Journal

Journal of Interventional Cardiology – Wiley

Published: Apr 1, 2002

There are no references for this article.